Insulin signaling to hepatic lipid metabolism in health and disease

Critical Reviews in Biochemistry and Molecular Biology

Volumn 46, Issue 3, 2011, Pages 200-215

  Leavens, Karla F ^a   Birnbaum, Morris J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 322 Clinical Research Building ^*  (United States)

Author keywords

Akt; Lipids; liver; SREBP1c; steatosis; triglyceride

Indexed keywords

FATTY ACID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; TRANSCRIPTION FACTOR NKX6.1; TRIACYLGLYCEROL;

DYSLIPIDEMIA; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIVER METABOLISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

DYSLIPIDEMIAS; FATTY LIVER; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIVER; NUCLEAR PROTEINS; ONCOGENE PROTEIN V-AKT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

MAMMALIA;

EID: 79956338241     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2011.562481     Document Type: Review

References (156)

1. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionoiri F, Yahagi N, Kadowaki T, Tamemoto H, Ishibashi S, Yazaki Y, Makuuchi M. 1998. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784-1788. (Pubitemid 28198509)
2. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis G F. 2001. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 11:170-176. (Pubitemid 32946865)
3. Alessi DR, James SR, Downes CP, Holmes AB, Gafney PR, Reese CB, Cohen P. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261-269. (Pubitemid 27176852)
4. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. 2004. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114:1493-1503. (Pubitemid 40385579)
5. Anderson N, Borlak J. 2008. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60:311-357.
6. Angulo P, Lindor KD. 2002. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17 Suppl:S186-S190. (Pubitemid 34539308)
7. Araki E, Lipes MA, Patti ME, Brüning JC, Haag B 3rd, Johnson RS, Kahn CR. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190. (Pubitemid 24347839)
8. Azain MJ, Fukuda N, Chao FF, Yamamoto M, Ontko JA. 1985. Contributions of fatty acid and sterol synthesis to triglyceride and cholesterol secretion by the perfused rat liver in genetic hyperlipemia and obesity. J Biol Chem 260:174-181. (Pubitemid 15165299)
9. Bécard D, Hainault I, Azzout-Marniche D, Bertry-Coussot L, Ferré P, Foufelle F. 2001. Adenovirus-mediated overexpression of sterol regulatory element binding protein-1c mimics insulin efects on hepatic gene expression and glucose homeostasis in diabetic mice. Diabetes 50:2425-2430. (Pubitemid 33642757)
10. Bengoechea-Alonso MT, Ericsson J. 2009. A phosphorylation cascade controls the degradation of active SREBP1. J Biol Chem 284:5885-5895.
11. Bergman RN. 2000. Non-esterifed fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43:946-952. (Pubitemid 30463177)
12. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. 2008. Hepatic insulin resistance is sufcient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7:125-134. (Pubitemid 351168555)
13. Boyko EJ. 2010. ACCORD glycemia results continue to puzzle. Diabetes Care 33:1149-1150.
14. Bozulic L, Hemmings BA. 2009. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 21:256-261.
15. Brown MS, Goldstein JL. 2008. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95-96. (Pubitemid 351168559)
16. Brown NF, Stefanovic-Racic M, Sipula IJ, Perdomo G. 2007. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metab Clin Exp 56:1500-1507. (Pubitemid 47562500)
17. Browning JD, Horton JD. 2004. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152. (Pubitemid 39071617)
18. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868. (Pubitemid 29165088)
19. Burgess SC, Iizuka K, Jeoung NH, Harris RA, Kashiwaya Y, Veech RL, Kitazume T, Uyeda K. 2008. Carbohydrate-response element-binding protein deletion alters substrate utilization producing an energy-defcient liver. J Biol Chem 283:1670-1678.
20. Carpentier A, Taghibiglou C, Leung N, Szeto L, Van Iderstine SC, Ufelman KD, Buckingham R, Adeli K, Lewis GF. 2002. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277:28795-28802.
21. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. 2001. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15:2203-2208. (Pubitemid 32843832)
22. Chirieac D V, Chirieac LR, Corsetti J P, Cianci J, Sparks CE, Sparks JD. 2000. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab 279:E1003-E1011.
23. -/- mice. Am J Physiol Gastrointest Liver Physiol 291:G382-G388. (Pubitemid 44330157)
24. Cho H, Mu J, Kim JK, Torvaldsen JL, Chu Q, Crenshaw EB 3rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. 2001a. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731. (Pubitemid 32506248)
25. Cho H, Torvaldsen JL, Chu Q, Feng F, Birnbaum MJ. 2001b. Akt1/ PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276:38349-38352.
26. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. 2002. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:240-243. (Pubitemid 34761283)
27. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789. (Pubitemid 26004411)
28. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C. 2006. Liver-specifc inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 55:2159-2170. (Pubitemid 44743612)
29. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J 3rd, Montminy M. 2007. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449:366-369. (Pubitemid 47443476)
30. Dentin R, Pégorier JP, Benhamed F, Foufelle F, Ferré P, Fauveau V, Magnuson MA, Girard J, Postic C. 2004. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 279:20314-20326. (Pubitemid 38623477)
31. Diraison F, Beylot M. 1998. Role of human liver lipogenesis and reesterifcation in triglycerides secretion and in FFA reesterifcation. Am J Physiol 274:E321-E327.
32. Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M. 2002. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab 282:E46-E51. (Pubitemid 34654105)
33. Diraison F, Moulin P, Beylot M. 2003. Contribution of hepatic de novo lipogenesis and reesterifcation of plasma non-esterifed fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29:478-485. (Pubitemid 37474259)
34. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White M F. 2008. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 8:65-76. (Pubitemid 351863393)
35. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-1351. (Pubitemid 40629054)
36. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39:171-183.
37. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. 2005. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25:1869-1878. (Pubitemid 40280150)
38. Estall JL, Kahn M, Cooper MP, Fisher FM, Wu MK, Laznik D, Qu L, Cohen DE, Shulman GI, Spiegelman BM. 2009. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 58:1499-1508.
39. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. 2009. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 106:15430-15435.
40. Fabbrini E, Sullivan S, Klein S. 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679-689.
41. Fleischmann M, Iynedjian PB. 2000. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J 349:13-17. (Pubitemid 30440159)
42. Forcheron F, Cachefo A, Tevenon S, Pinteur C, Beylot M. 2002. Mechanisms of the triglyceride- and cholesterol-lowering efect of fenofbrate in hyperlipidemic type 2 diabetic patients. Diabetes 51:3486-3491. (Pubitemid 35403454)
43. Foretz M, Guichard C, Ferré P, Foufelle F. 1999. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 96:12737-12742. (Pubitemid 29513572)
44. Foster KG, Fingar DC. 2010. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285:14071-14077.
45. Garofalo RS, Orena SJ, Rafdi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD, Coleman KG. 2003. Severe diabetes, age-dependent loss of adipose tissue, and mild growth defciency in mice lacking Akt2/PKB beta. J Clin Invest 112:197-208. (Pubitemid 38056356)
46. Ginsberg HN, Zhang YL, Hernandez-Ono A. 2005. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36:232-240. (Pubitemid 40755136)
47. Gross DN, van den Heuvel AP, Birnbaum MJ. 2008. The role of FoxO in the regulation of metabolism. Oncogene 27:2320-2336. (Pubitemid 351501783)
48. Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV, White MF. 2009. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29:5070-5083.
49. Gutiérrez-Juárez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, Rossetti L. 2006. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 116:1686-1695.
50. Han S, Liang CP, Westerterp M, Senokuchi T, Welch CL, Wang Q, Matsumoto M, Accili D, Tall AR. 2009. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest 119:1029-1041.
51. Hanada M, Feng J, Hemmings BA. 2004. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697:3-16. (Pubitemid 38326757)
52. Harada N, Oda Z, Hara Y, Fujinami K, Okawa M, Ohbuchi K, Yonemoto M, Ikeda Y, Ohwaki K, Aragane K, Tamai Y, Kusunoki J. 2007. Hepatic de novo lipogenesis is present in liver-specifc ACC1-defcient mice. Mol Cell Biol 27:1881-1888.
53. He L, Hou X, Kanel G, Zeng N, Galicia V, Wang Y, Yang J, Wu H, Birnbaum MJ, Stiles BL. 2010. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am J Pathol 176:2302-2308.
54. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S, Wondisford FE. 2009. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137:635-646.
55. Hegarty BD, Bobard A, Hainault I, Ferré P, Bossard P, Foufelle F. 2005. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc Natl Acad Sci USA 102:791-796. (Pubitemid 40282744)
56. Hillgartner FB, Salati LM, Goodridge AG. 1995. Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis. Physiol Rev 75:47-76.
57. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T. 2004. Hepatocyte-specifc Pten defciency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113:1774-1783. (Pubitemid 39071669)
58. Horton JD. 2002. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 30:1091-1095. (Pubitemid 36002414)
59. Horton JD, Bashmakov Y, Shimomura I, Shimano H. 1998a. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA 95:5987-5992. (Pubitemid 28248951)
60. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. 1998b. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 101:2331-2339. (Pubitemid 28270427)
61. Hresko RC, Mueckler M. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406-40416. (Pubitemid 41780527)
62. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. 2004. Defciency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 101:7281-7286. (Pubitemid 38638024)
63. Iizuka K, Miller B, Uyeda K. 2006. Defciency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-defcient (ob/ob) mice. Am J Physiol Endocrinol Metab 291:E358-E364. (Pubitemid 44043073)
64. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Tomas A, Weiss D, Hramiak I. 2010. Efect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419-430.
65. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689. (Pubitemid 32893993)
66. Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M, Ronan J, Esau C, Murphy C, Szalkowski D, Bergeron R, Doebber T, Zhang BB. 2005. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 115:1030-1038. (Pubitemid 40489408)
67. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. 2008. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 118:2347-2364. (Pubitemid 351872351)
68. Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K. 2001. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci USA 98:13710-13715. (Pubitemid 33115963)
69. Kerouz NJ, Hörsch D, Pons S, Kahn CR. 1997. Diferential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 100:3164-3172. (Pubitemid 28022855)
70. Khamzina L, Veilleux A, Bergeron S, Marette A. 2005. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 146:1473-1481. (Pubitemid 40289337)
71. Koo SH, Dutcher AK, Towle HC. 2001. Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem 276:9437-9445.
72. Koo SH, Towle HC. 2000. Glucose regulation of mouse S(14) gene expression in hepatocytes. Involvement of a novel transcription factor complex. J Biol Chem 275:5200-5207. (Pubitemid 30108924)
73. Kubota N, Kubota T, Itoh S, Kumagai H, Kozono H, Takamoto I, Mineyama T, Ogata H, Tokuyama K, Ohsugi M, Sasako T, Moroi M, Sugi K, Kakuta S, Iwakura Y, Noda T, Ohnishi S, Nagai R, Tobe K, Terauchi Y, Ueki K, Kadowaki T. 2008. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8:49-64. (Pubitemid 351859226)
74. Kuriyama H, Liang G, Engelking LJ, Horton JD, Goldstein JL, Brown MS. 2005. Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional defciency of SCAP in liver. Cell Metab 1:41-51. (Pubitemid 43960583)
75. Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianfone K, Sonenberg N. 2007. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 117:387-396. (Pubitemid 46203967)
76. Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. 2009. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab 10:405-418.
77. Lee WN, Bassilian S, Lim S, Boros LG. 2000. Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. Am J Physiol Endocrinol Metab 279:E425-E432.
78. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly-Y M, Storlien L, Strömstedt M, Snaith M, Oresic M, Abel ED, Cannon B, Vidal-Puig A. 2006. Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol 4:e369.
79. Leone TC, Lehman JJ, Finck BN, Schaefer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saftz JE, Abel ED, Semenkovich CF, Kelly DP. 2005. PGC-1alpha defciency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3:e101.
80. Li S, Brown MS, Goldstein JL. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 107:3441-3446.
81. Li X, Grundy SM, Patel SB. 1997. Obesity in db and ob animals leads to impaired hepatic very low density lipoprotein secretion and diferential secretion of apolipoprotein B-48 and B-100. J Lipid Res 38:1277-1288. (Pubitemid 27332556)
82. Li X, Monks B, Ge Q, Birnbaum MJ. 2007. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447:1012-1016. (Pubitemid 46975750)
83. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. 2002. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective defciency of sterol regulatory element-binding protein-1c. J Biol Chem 277:9520-9528. (Pubitemid 34953041)
84. Liao W, Hui TY, Young SG, Davis RA. 2003. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 44:978-985. (Pubitemid 37279657)
85. Lin J, Handschin C, Spiegelman BM. 2005. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361-370. (Pubitemid 43960626)
86. Luong N, Davies CR, Wessells RJ, Graham SM, King MT, Veech R, Bodmer R, Oldham SM. 2006. Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab 4:133-142. (Pubitemid 44138719)
87. Lusis AJ, Attie AD, Reue K. 2008. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 9:819-830.
88. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, Shaikenov TE, Kordari P, Chirala SS, Heird WC, Wakil SJ. 2006. Liver-specifc deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without afecting glucose homeostasis. Proc Natl Acad Sci USA 103:8552-8557. (Pubitemid 43838493)
89. Matsuda M, Korn BS, Hammer RE, Moon YA, Komuro R, Horton JD, Goldstein JL, Brown MS, Shimomura I. 2001. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 15:1206-1216. (Pubitemid 32472750)
90. Matsumoto M, Han S, Kitamura T, Accili D. 2006. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 116:2464-2472. (Pubitemid 44330145)
91. Matsumoto M, Ogawa W, Akimoto K, Inoue H, Miyake K, Furukawa K, Hayashi Y, Iguchi H, Matsuki Y, Hiramatsu R, Shimano H, Yamada N, Ohno S, Kasuga M, Noda T. 2003. PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 112:935-944. (Pubitemid 38063751)
92. McGarry JD. 1992. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258:766-770.
93. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6:87-97.
94. Miyake K, Ogawa W, Matsumoto M, Nakamura T, Sakaue H, Kasuga M. 2002. Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. J Clin Invest 110:1483-1491. (Pubitemid 35396919)
95. Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, Ntambi JM. 2007. Hepatic stearoyl-CoA desaturase-1 defciency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 6:484-496. (Pubitemid 350163054)
96. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, Romanelli AJ, Cline GW, Pongratz RL, Zhang XM, Choi CS, Coleman RA, Shulman GI. 2005. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab 2:55-65. (Pubitemid 43239825)
97. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99:11482-11486. (Pubitemid 34920951)
98. Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, Onishi Y, Anai M, Ogihara T, Fujishiro M, Viana AY, Fukushima Y, Abe M, Shojima N, Kikuchi M, Yamada N, Oka Y, Asano T. 2003. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52:2905-2913. (Pubitemid 37466859)
99. Parekh S, Anania FA. 2007. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132:2191-2207. (Pubitemid 46693752)
100. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Torens B, Tomas G. 2000. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-defcient mice. Nature 408:994-997. (Pubitemid 32103292)
101. Pocai A, Obici S, Schwartz GJ, Rossetti L. 2005. A brain-liver circuit regulates glucose homeostasis. Cell Metab 1:53-61. (Pubitemid 43960581)
102. Porstmann T, Grifths B, Chung YL, Delpuech O, Grifths JR, Downward J, Schulze A. 2005. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465-6481. (Pubitemid 41486630)
103. Porstmann T, Santos CR, Grifths B, Cully M, Wu M, Leevers S, Grifths JR, Chung YL, Schulze A. 2008. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8:224-236.
104. Postic C, Dentin R, Denechaud PD, Girard J. 2007. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr 27:179-192. (Pubitemid 351373354)
105. Postic C, Girard J. 2008a. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118:829-838. (Pubitemid 351364588)
106. Postic C, Girard J. 2008b. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 34:643-648.
107. Punga T, Bengoechea-Alonso MT, Ericsson J. 2006. Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem 281:25278-25286. (Pubitemid 44401915)
108. Reilly MP, Rader DJ. 2003. The metabolic syndrome: more than the sum of its parts? Circulation 108:1546-1551. (Pubitemid 37187778)
109. Ribaux PG, Iynedjian PB. 2003. Analysis of the role of protein kinase B (cAKT) in insulin-dependent induction of glucokinase and sterol regulatory element-binding protein 1 (SREBP1) mRNAs in hepatocytes. Biochem J 376:697-705. (Pubitemid 38058068)
110. Roach PJ. 2002. Glycogen and its metabolism. Curr Mol Med 2:101-120. (Pubitemid 34649835)
111. Sajan MP, Standaert ML, Nimal S, Varanasi U, Pastoor T, Mastorides S, Braun U, Leitges M, Farese R V. 2009. The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity. J Lipid Res 50:1133-1145.
112. Saltiel AR. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529. (Pubitemid 32201947)
113. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101. (Pubitemid 40262113)
114. Satapati S, He T, Inagaki T, Potthof M, Merritt ME, Esser V, Mangelsdorf DJ, Kliewer SA, Browning JD, Burgess SC. 2008. Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes 57:2012-2021.
115. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, Bhanot S, Monia BP, Shulman GI. 2006. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116:817-824. (Pubitemid 43326891)
116. Schwarz JM, Linfoot P, Dare D, Aghajanian K. 2003. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77:43-50. (Pubitemid 36015371)
117. Schwarz JM, Neese RA, Turner S, Dare D, Hellerstein MK. 1995. Short-term alterations in carbohydrate energy intake in humans. Striking efects on hepatic glucose production, de nov o lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest 96:2735-2743.
118. Sengupta S, Peterson TR, Sabatini DM. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40:310-322.
119. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. 1996. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98:1575-1584. (Pubitemid 26327867)
120. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. 1997a. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99:846-854. (Pubitemid 27123620)
121. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD. 1997b. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 100:2115-2124. (Pubitemid 27459368)
122. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N. 1999. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274:35832-35839. (Pubitemid 129512888)
123. Shimomura I, Bashmakov Y, Horton JD. 1999a. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274:30028-30032.
124. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. 1999b. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96:13656-13661.
125. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. 1997. Diferential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838-845. (Pubitemid 27123619)
126. Shimomura I, Shimano H, Korn BS, Bashmakov Y, Horton JD. 1998. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 273:35299-35306. (Pubitemid 29028238)
127. Simmgen M, Knauf C, Lopez M, Choudhury AI, Charalambous M, Cantley J, Bedford DC, Claret M, Iglesias MA, Hefron H, Cani PD, Vidal-Puig A, Burcelin R, Withers DJ. 2006. Liver-specifc deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice. Diabetologia 49:552-561. (Pubitemid 43277879)
128. Sonoda J, Mehl IR, Chong LW, Nofsinger RR, Evans RM. 2007. PGC-1beta controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci USA 104:5223-5228. (Pubitemid 47186203)
129. Sparks JD, Sparks CE. 1994. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215:9-32. (Pubitemid 24345052)
130. Sparks JD, Sparks CE, Miller LL. 1989. Insulin efects on apolipoprotein B production by normal, diabetic and treated-diabetic rat liver and cultured rat hepatocytes. Biochem J 261:83-88. (Pubitemid 19174764)
131. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gafney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT. 1998. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate- dependent activation of protein kinase B. Science 279:710-714. (Pubitemid 28144551)
132. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H. 2004. Liver-specifc deletion of
133. Stoeckman AK, Towle HC. 2002. The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression. J Biol Chem 277:27029-27035. (Pubitemid 34951715)
134. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, Ericsson J. 2005. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 1:379-391. (Pubitemid 43960622)
135. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K. 2000. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 275:8416-8425. (Pubitemid 30180185)
136. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186. (Pubitemid 24347838)
137. Taniguchi CM, Emanuelli B, Kahn CR. 2006a. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85-96. (Pubitemid 43278292)
138. Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR. 2006b. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 3:343-353.
139. Taniguchi CM, Ueki K, Kahn R. 2005. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718-727. (Pubitemid 40322247)
140. Taskinen MR. 2003. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749.
141. Teleman AA, Chen YW, Cohen SM. 2005. 4E-BP functions as a metabolic brake used under stress conditions but not during normal growth. Genes Dev 19:1844-1848. (Pubitemid 41186984)
142. Timlin MT, Parks EJ. 2005. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 81:35-42. (Pubitemid 43073373)
143. Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, Terauchi Y, Matsui J, Akanuma Y, Kimura S, Tanaka J, Abe M, Ohsumi J, Nagai R, Kadowaki T. 2001. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J Biol Chem 276:38337-38340.
144. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Tomas G. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205. (Pubitemid 39243474)
145. WHO 2008. Fact Sheet: The Top Ten Causes of Death. In: World Health Organization, M. C. (ed.) http://www.who.int/mediacentre/ factsheets/fs310/en/ index.html.
146. Wiegman CH, Bandsma RH, Ouwens M, van der Sluijs FH, Havinga R, Boer T, Reijngoud DJ, Romijn JA, Kuipers F. 2003. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive efects of insulin. Diabetes 52:1081-1089. (Pubitemid 36523340)
147. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-904. (Pubitemid 28157668)
148. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stofel M. 2004. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432:1027-1032. (Pubitemid 40052233)
149. Wolfrum C, Stofel M. 2006. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 3:99-110.
150. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N. 2002. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277:19353-19357. (Pubitemid 34967441)
151. Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, Shillinglaw W, Arnot D, Uyeda K. 2001. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci USA 98:9116-9121. (Pubitemid 32743878)
152. Yang J, Goldstein JL, Hammer RE, Moon YA, Brown MS, Horton JD. 2001. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc Natl Acad Sci USA 98:13607-13612. (Pubitemid 33115945)
153. Zhang L, Rubins NE, Ahima RS, Greenbaum LE, Kaestner KH. 2005. Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab 2:141-148.
154. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajan MP, Farese RV, Stolz DB, Tso P, Koo SH, Montminy M, Unterman TG. 2006. FoxO1 regulates multiple metabolic pathways in the liver: efects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 281:10105-10117. (Pubitemid 43864546)
155. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. 2004a. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18:157-169. (Pubitemid 38141784)
156. Zhang YL, Hernandez-Ono A, Ko C, Yasunaga K, Huang LS, Ginsberg HN. 2004b. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Diferential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 279:19362-19374. (Pubitemid 38623367)